G-PBSC infusion improves the probability of DFS and OS for elderly patients with AML. (A) The probabilities of 2-year DFS and OS were 38.9% and 39.3%, respectively, in the G-PBSC group. These rates are significantly higher than those in the control group (10.0% and 10.3%, respectively; P = .01 and P = .0006). (B) The patients whose donor associated with HLA-C2 ligands (n = 13) had significantly higher OS compared with donor having no C2 ligands (n = 17) in the G-PBSC group (57.1% vs 12.5%; P = .01).